Interpace Biosciences Announces CFO Leadership Transition
February 04, 2021 16:42 ET
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) (“Interpace”) a leader in enabling personalized medicine, announced today that its Board of Directors has...
CYBIN Closes Acquisition of Adelia Therapeutics; Bolsters Scientific Team and Grows IP Portfolio to 7 Patent Filings
December 14, 2020 08:07 ET
|
Cybin Inc.
--Newly acquired novel psychedelic molecules diversify Cybin’s development portfolio, providing access to multiple future indications-- --Adelia brings a range of technologies related to novel...
Corbus Pharmaceuticals to Report Fourth Quarter and Year-End 2019 Results on March 12, 2020
March 05, 2020 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
- Management to host conference call and webcast on Thursday, March 12 at 8:30 a.m. ET - Norwood, MA, March 05, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP)...
Corbus Pharmaceuticals Completes Enrollment of Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis
November 18, 2019 08:17 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Company expects to report topline data from study in the summer of 2020Primary endpoint of this study is reduction in pulmonary exacerbationsStudy enrolled participants regardless of CFTR mutation...
Corbus Pharmaceuticals Reports 2019 Second Quarter Financial Results and Provides Clinical and Corporate Updates
August 08, 2019 07:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Clinical development of lenabasum on target for 2020 data readouts in lead indications systemic sclerosis and cystic fibrosis; diseases affect ~270,000 people total in U.S., EU and Japan CRB-4001 on...
Corbus Pharmaceuticals to Present at the Oppenheimer 29th Annual Healthcare Conference
March 11, 2019 08:35 ET
|
Corbus Pharmaceuticals Holdings, Inc.
- Presentation with live audio webcast on Tuesday, March 19, 2019 at 2:10 p.m. ET- Norwood, MA, March 11, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or...
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in November
November 06, 2018 08:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
– Jefferies 2018 London Healthcare Conference presentation with live audio webcast on Thursday, November 15 at 4:40 p.m. GMT – – 30th Annual Piper Jaffray Healthcare Conference presentation with...
Corbus Pharmaceuticals Appoints Former Director of FDA Office of New Drugs John K. Jenkins, MD to Board of Directors
June 06, 2018 07:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
– Distinguished 25-year career serving at the U.S. Food and Drug Administration, including 15 years of senior leadership in CDER and OND – – Appointment brings regulatory experience to the Board of...
Corbus Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference
May 24, 2018 08:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
- Live audio presentation and webcast on Wednesday, June 6th at 9:00 a.m. EDT - Norwood, MA, May 24, 2018 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or...
Corbus Pharmaceuticals Adds Two Key Executives to Lead its Regulatory and CMC Operations
May 22, 2018 08:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
— Robert Discordia, Ph.D., named Vice President, Pharmaceutical Development & Manufacturing — — Ross Lobell named Vice President, Regulatory Affairs — Norwood, MA, May 22, 2018 (GLOBE...